Access to risk finance
Access to risk finance aims to overcome deficits in the availability of debt and equity finance for R&D and innovation-driven companies and projects at all stages of development by supporting the development of Union-level venture capital.
Your NCP contacts for this programme
Please contact
info@ncpflanders.be
+32 2 550 15 65
About this programme
The concrete goal of access to risk finance under Horizon 2020 is to support and facilitate access to sources of debt and equity financing by innovative companies of all sizes and also by research centers and universities etc.
This support is given through financial intermediaries.
Latest news
EIC FET Risk Finance SME Instrument
European Innovation Procurement Awards call open for submission
From today the call for The European Innovation Procurement Awards is open for submission. The deadline of the call is 29 July at 17 hours Brussels time. As explained in the European Innovation Council 2021 work programme the awards aim to “recognise public and private buyers across Europe in their efforts to promote innovation procureme... read more
Upcoming events
Work Programme & Calls
Infosheets
Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.
-
No infosheets available for this domain
Related links
Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.
Documents
Documents contain additional information related to this programme, and are similar to related links.
Testimonial
Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
